FCN1 and plasma cell myeloma: The ROC analysis demonstrated high potential of ficolin-1 to discriminate not only between AML patients and healthy controls but also between AML patients and individuals suffering from other haematological malignancies [multiple myeloma or lymphomas; detailed data concerning serum concentrations of ficolins in those patients were recently published27 (Table 4).